Xilio Therapeutics, Inc. (XLO)
- Previous Close
0.9412 - Open
0.9411 - Bid 0.8800 x 100
- Ask 0.9205 x 100
- Day's Range
0.8510 - 0.9411 - 52 Week Range
0.4900 - 1.9300 - Volume
130,295 - Avg. Volume
258,089 - Market Cap (intraday)
38.683M - Beta (5Y Monthly) -0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5500 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.50
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
xiliotx.comRecent News: XLO
View MorePerformance Overview: XLO
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XLO
View MoreValuation Measures
Market Cap
41.37M
Enterprise Value
-11.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.01
Price/Book (mrq)
1.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-52.58%
Return on Equity (ttm)
-170.96%
Revenue (ttm)
4.62M
Net Income Avi to Common (ttm)
-62.8M
Diluted EPS (ttm)
-1.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
61.26M
Total Debt/Equity (mrq)
40.12%
Levered Free Cash Flow (ttm)
-3.04M